HOME >> BIOLOGY >> NEWS
Studies offer data on potential impact of Reminyl on caregiver 'burden' in Alzheimer's disease

r greater of patients included nausea, vomiting, anorexia, diarrhea and weight loss.

Reminyl is available by prescription in 4 mg, 8 mg or 12 mg tablets, as well as in an oral solution (4mg/ml). It should be taken by patients twice a day, preferably with morning and evening meals. It is recommended that physicians start by prescribing 8 mg of Reminyl per day (in two divided doses) for at least four weeks, then increase to the recommended maintenance dose of 16 mg per day. Physicians have the flexibility to increase the daily dose to 24 mg after an additional four weeks. More information on the product, including full prescribing information, can be found at www.reminyl.com.

About Reminyl

Reminyl was first approved in Sweden in March of 2000, for the treatment of mild to moderate Alzheimers disease. It is believed that Reminyl inhibits an enzyme that breaks down acetylcholine a chemical in the brain that plays a key role in memory and learning. It also is believed that Reminyl modulates the brains nicotinic receptors, to which acetylcholine binds. Laboratory research suggests that through this modulation, Reminyl stimulates greater release of acetylcholine. Research designed to define the significance of this finding in humans is underway.


'"/>

Contact: Andrew Cooper
andrew.cooper@ketchum.com
44-020-7611-3859
Ketchum
13-Sep-2001


Page: 1 2 3 4

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies of rare blood syndrome yield novel route to cancer
8. Studies dispute ultraviolet effect on amphibian population declines
9. Studies of spiders silk reveal unusual strength
10. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 2015  Analyst Report Issued by Small Cap IR. In 2011, ... planet-wide, transactions at merchants on the leading payment cards rose ... credit, debit, and prepaid cards reached 6.54 billion.  Eight million ... card usage in 2012, and credit and debit card fraud ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
(Date:2/27/2015)... and SUMMERLAND, British Columbia , ... XON ), a leader in synthetic biology, ... acquire  Okanagan Specialty Fruits (OSF), the pioneering agricultural ... the world,s first non-browning apple. Through the acquisition, Intrexon ... that is more appetizing and convenient for consumers while ...
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... studies for its newly developed Bruton,s tyrosine kinase ... been completed. The results of these preclinical evaluations ... Drug Administration. The feedback received from the Agency ... first-in-human study. Additional preclinical work is required to ...
(Date:2/27/2015)... A paper published today, " Financing ... in Science Translational Medicine, demonstrates the ... the risk associated with investing in the treatment ... of funding for developing so-called "orphan" drugs. ... between scientists at the National Center for Advancing ...
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their offering. ... 9002-07-7) aims at providing comprehensive data on Trypsin globally and ... , North America , Latin ... close attention to Trypsin This report focuses on ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Global Market Report of Trypsin 2014-2018 2
Cached News: